These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 28082438)

  • 1. The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis.
    Barrio M; Czernin J; Fanti S; Ambrosini V; Binse I; Du L; Eiber M; Herrmann K; Fendler WP
    J Nucl Med; 2017 May; 58(5):756-761. PubMed ID: 28082438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
    Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
    J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gallium-68-dotatate PET/CT is better than CT in the management of somatostatin expressing tumors: First experience in Africa.
    Lawal IO; Ololade KO; Lengana T; Reyneke F; Ankrah AO; Ebenhan T; Vorster M; Sathekge MM
    Hell J Nucl Med; 2017; 20(2):128-133. PubMed ID: 28697189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Quantification of immunohistochemical expression of somatostatin receptors in neuroendocrine tumors using 68Ga-DOTATATE PET/CT].
    Haug AR; Assmann G; Rist C; Tiling R; Schmidt GP; Bartenstein P; Hacker M
    Radiologe; 2010 Apr; 50(4):349-54. PubMed ID: 20333502
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Delpassand ES; Ranganathan D; Wagh N; Shafie A; Gaber A; Abbasi A; Kjaer A; Tworowska I; Núñez R
    J Nucl Med; 2020 Jun; 61(6):890-896. PubMed ID: 31924723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of using [
    Leupe H; Pauwels E; Vandamme T; Van den Broeck B; Lybaert W; Dekervel J; Van Herpe F; Jaekers J; Cleeren F; Hofland J; Brouwers A; Koole M; Bormans G; Van Cutsem E; Geboes K; Laenen A; Verslype C; Stroobants S; Deroose CM
    J Neuroendocrinol; 2024 Aug; 36(8):e13420. PubMed ID: 38837825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Observation on enhanced avidity on somatostatin receptor targeted 68Ga-DOTATATE PET-CT following therapy with everolimus and capecitabine-temozolamide: is redifferentiation akin phenomenon a reality in neuroendocrine tumors?
    Basu S; Ostwal V
    Nucl Med Commun; 2016 Jun; 37(6):669-71. PubMed ID: 27105440
    [No Abstract]   [Full Text] [Related]  

  • 10. ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors.
    Subramaniam RM; Bradshaw ML; Lewis K; Pinho D; Shah C; Walker RC
    Clin Nucl Med; 2018 Dec; 43(12):899-908. PubMed ID: 30394933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head-to-Head Comparison of
    Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
    J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic 68Ga-DOTATOC PET/CT and static image in NET patients. Correlation of parameters during PRRT.
    Van Binnebeek S; Koole M; Terwinghe C; Baete K; Vanbilloen B; Haustermans K; Clement PM; Bogaerts K; Verbruggen A; Nackaerts K; Van Cutsem E; Verslype C; Mottaghy FM; Deroose CM
    Nuklearmedizin; 2016 Jun; 55(3):104-14. PubMed ID: 27056060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between lesion tracer uptake on 68Ga-DOTATATE PET with morphological response to 177Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors.
    Metser U; Eshet Y; Ortega C; Veit-Haibach P; Liu A; K S Wong R
    Nucl Med Commun; 2022 Jan; 43(1):73-77. PubMed ID: 34887370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours.
    Virgolini I; Gabriel M; Kroiss A; von Guggenberg E; Prommegger R; Warwitz B; Nilica B; Roig LG; Rodrigues M; Uprimny C
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2072-83. PubMed ID: 27174220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management.
    Kunikowska J; Lewington V; Krolicki L
    Clin Nucl Med; 2017 Dec; 42(12):905-911. PubMed ID: 29076910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical value of
    Ma H; Kan Y; Yang JG
    Acta Radiol; 2021 Sep; 62(9):1217-1228. PubMed ID: 32985224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic utility of Gallium-68-somatostatin receptor PET/CT in ectopic ACTH-secreting tumors: a systematic literature review and single-center clinical experience.
    Varlamov E; Hinojosa-Amaya JM; Stack M; Fleseriu M
    Pituitary; 2019 Oct; 22(5):445-455. PubMed ID: 31236798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on
    Gålne A; Almquist H; Almquist M; Hindorf C; Ohlsson T; Nordenström E; Sundlöv A; Trägårdh E
    J Nucl Med; 2019 Dec; 60(12):1717-1723. PubMed ID: 31000584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.